US OptionsDetailed Quotes

NXTC250117P2500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jan 10 07:07
    NEWS
    $NextCure (NXTC.US)$
    NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
    Friday, 10th January at 8:05 am
    BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B...
    Jaguar8
    Jaguar8
    Dec 10, 2024 07:05
    NEWS
    $NextCure (NXTC.US)$
    NextCure Announces Acceptance of IND Application for LNCB74
    Tuesday, 10th December at 8:05 am
    BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of a Phase 1 c...
    Jaguar8
    Jaguar8
    Nov 19, 2024 07:07
    NEWS
    $NextCure (NXTC.US)$
    Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
    NextCure announced preclinical data showing that NC605, their anti-Siglec-15 antibody, enhanced quality bone generation with improved mechanical properties in mice with Osteogenesis Imperfecta (OI). The study used NP159, a surrogate antibody to NC605, at 20 mg/kg dosage. Key results showed 90% ...
    Jaguar8
    Jaguar8
    Nov 5, 2024 15:10
    NEWS
    $NextCure (NXTC.US)$
    NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
    NextCure (NXTC) presented preclinical data for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC), and additional biomarker data for NC410 combination therapy at SITC. LNCB74 showed promising results with strong anti-tumor activity in multiple tumor models and favorable safety profile, with IND filing expected by y...
Read more